Navigation Links
Cell Therapeutics, Inc. (CTI) Reports Fourth Quarter and Year-End Financial Results and Milestones

SEATTLE, March 7, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI" or the "Company") (NASDAQ and MTA: CTIC) today reported financial results and recent accomplishments for the fourth quarter and year ended December 31, 2011.

Fourth Quarter and Year End ResultsFor the quarter ended December 31, 2011, total net operating expenses were $9.9 million compared to $16.3 million for the same period in 2010. Net loss attributable to common shareholders was $17.9 million ($0.09 per share) for the quarter ended December 31, 2011 compared to a net loss attributable to common shareholders of $34.1 million ($0.27 per share) for the same period in 2010. The decrease in net loss attributable to our common shareholders is mainly due to a $11.0 million gain related to a litigation settlement and decrease in non-cash deemed dividends on preferred stock issuances in the quarter ended December 31, 2011.

For the year ended December 31, 2011, total net operating expenses declined to $62.2 million, which included an upfront payment of $5.0 million related to the licensing of tosedostat from Chroma Therapeutics Ltd., compared to $75.1 million for the same period in 2010.  Net loss attributable to common shareholders was $121.1 million ($0.71 per share), compared to a net loss attributable to common shareholders of $147.6 million ($1.29 per share) for the same period in 2010. For the year ended December 31, 2011, the decrease in net loss attributable to common shareholders is mainly due to a decrease in selling, general and administrative expenses, a $11.0 million gain related to a litigation settlement and decrease in non-cash deemed dividends on preferred stock issuances.  

CTI had approximately $47.1 million in cash and cash equivalents as of December 31, 2011.

Recent HighlightsIn February 2012, the European Medicines Agency's ("EMA") Committee for Human Medicinal Products ("CHMP") granted a positive opinion for conditional approval of CTI's marketing authorization application (the "MAA") for Pixuvri to treat adult patients with multiple relapsed or refractory aggressive non-Hodgkin B-cell lymphomas ("NHL").

"We expect that in the next few months the European Commission should adopt the CHMP's opinion for this unmet medical need and for the first time patients with multiple relapsed or refractory aggressive NHL in the E.U. will have an approved therapy to treat their disease," stated James A. Bianco, M.D., CEO of Cell Therapeutics, Inc. "We are working with consultants on developing a staffing, resource and product launch plan for Europe so upon marketing authorization and national reimbursement approvals, we can be in a position to bring Pixuvri to these patients.  With approximately 12,000 potential patients each year in the EU(1) this represents an attractive initial commercial opportunity for CTI."

"At the same time, we are moving our other late stage product candidates forward including a March meeting with the U.S. Food and Drug Administration for the phase 3 tosedostat trial in myelodysplastic syndrome ("MDS"), a precursor of acute myeloid leukemia ("AML"). Additionally a multi-center, phase 2 study with OPAXIO treating malignant brain cancer is underway based on encouraging results from the previous study in this disease. With the potential commercial launch of Pixuvri, coupled with the successful in-licensing of tosedostat, we continue to explore additional novel clinical stage compounds to expand our hematologic cancer product pipeline," Bianco added.

  • EMA's CHMP granted a positive opinion for conditional approval of CTI's MAA for Pixuvri as monotherapy for the treatment of adult patients with multiple relapsed or refractory aggressive NHL.
  • The final OPAL phase 2 results of tosedostat, which demonstrated significant response rates in elderly patients with refractory or relapsed AML, were presented in an oral session at the American Society of Hematology's Annual Meeting in 2011. CTI believes that encouraging survival rates in secondary AML provides rationale for phase 3 study in relapsed or refractory MDS.  
  • Retired all convertible debt.

  • Conference Call InformationOn Wednesday, March 7, 2012, at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time, members of CTI's management team will host a conference call to discuss CTI's 2011 fourth quarter and year-end achievements and financial results.

    Conference Call NumbersWednesday March 7, 2012 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time
    1-877-941-8609 (US Participants)
    1-480-629-9692 (International)

    Call-back numbers for post-listening available at 11:30 a.m. Eastern Time:
    1-800-406-7325 (US Participants)
    1-303-590-3030  (International)
    Passcode: 4521365#

    Live audio webcast at will be archived for post-call listening approximately two hours after call ends.

    About Cell Therapeutics, Inc.Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit

    (1) Potential patients per year is extrapolated from The World Health Organization's International Agency for Research on Cancer's 2008 GLOBOCAN database estimates of patients with NHL and publications of subtypes and relapse/refractory rates for the disease including Armitage JO, et al. A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lyphoma. Blood. 1997:11: 3909-3918 and Tilly H, Dreyling M. Diffuse Large B-Cell non-Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. Annals of Oncology. 2010: 5: 172-174.

    This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of CTI's securities. Specifically, the risks and uncertainties that could affect the development of CTI's drug candidates include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with pixantrone in particular, including, without limitation, the potential failure of pixantrone to prove safe and effective for the treatment of relapsed or refractory aggressive NHL and/or other tumors as determined by the FDA and/or the EMA, that Pixuvri may not be the first drug approved as monotherapy for the treatment of adult patients with multiple relapsed or refractory aggressive NHL, that the European Commission may not formally adopt the CHMP's recommendation regarding Pixuvri, that conditional approval of CTI's MAA for Pixuvri may not be granted by the European Commission within the next few months or at all, that Pixuvri may not be approved for marketing in all of the E.U. Member States and the European Economic Area members, that the EMA may request additional information from CTI regarding Pixuvri, the potential failure of tosedostat to prove safe and effective for the treatment of relapsed MDS, AML, multiple myeloma, blood related cancers and solid tumors as determined by the FDA and/or the EMA, that the FDA may not accept the proposed clinical trial of tosedostat and/or may request additional trials, that CTI may not meet with the FDA in March 2012 regarding the phase 3 clinical trial of tosedostat in MDS, that CTI may not acquire any additional novel clinical stage compounds to expand its hematologic cancer product pipeline, that CTI cannot predict or guarantee the pace or geography of enrollment of its clinical trials, that CTI may not be able to sustain its current cost controls, and that CTI may not be able to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone. Further risks and uncertainties include that CTI continues to have a substantial amount of debt outstanding and the quarterly interest expense associated with the debt is significant, CTI's operating expenses continue to exceed its net revenues, that CTI may not be able to further reduce its operating expenses, that CTI will continue to need to raise capital to fund its operating expenses and may not be able to raise sufficient amounts to fund its continued operation as well as other risks listed or described from time to time in CTI's most recent filings with the Securities and Exchange Commission on Forms 10-K, 10-Q and 8-K. Except as required by law, CTI does not intend to update any of the statements in this press release upon further developments.

    Media Contact:
    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    F: 206.272.4434

    Investors Contact:
    Ed Bell
    T: 206.282.7100
    Lindsey Jesch Logan
    T: 206.272.4347
    F: 206.272.4434
    E: Therapeutics, Inc.Condensed Consolidated Statements of Operations(In thousands, except for per share amounts)(unaudited)Three Months EndedYear EndedDecember 31,December 31,2011201020112010Revenues:License and contract revenue

    319Total revenues

    ---319Operating expenses, net:Research and development

    7,9187,65634,90027,031Selling, general and administrative

    12,9938,66538,29048,043Gain from litigation settlement

    (11,000)-(11,000)-Total operating expenses, net

    9,91116,32162,19075,074Loss from operations

    (9,911)(16,321)(62,190)(74,755)Other income (expense):Investment and other income, net

    1,6599811,7131,221Interest expense

    (183)(386)(1,038)(2,334)Amortization of debt discount and issuance costs

    (110)(168)(546)(768)Foreign exchange loss

    (502)(221)(558)(521)Debt conversion expense

    ---(2,031)Provision for VAT Assessments

    -(3,503)-(3,503)Settlement expense, net

    -(145)-(145)Net loss before noncontrolling interest

    (9,047)(19,763)(62,619)(82,836)Noncontrolling interest

    8045259194Net loss attributable to CTI

    (8,967)(19,718)(62,360)(82,642)Dividends and deemed dividends on preferred stock

    (8,901)(14,399)(58,718)(64,918)Net loss attributable to CTI common shareholders

    $ (17,868)$ (34,117)$  (121,078)$  (147,560)Basic and diluted net loss per common share

    (1.29)Shares used in calculation of basic and dilutednet loss per common share

    188,513126,659171,468114,105Balance Sheet Data (unaudited):(amounts in thousands)December 31, 20112010Cash and cash equivalents $
    22,649Working capital33,291(14,165)Total assets62,23953,592Convertible debt-22,308Accumulated deficit(1,714,785)(1,576,643)Total shareholders' equity (deficit)28,009(5,145)

    SOURCE Cell Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End 2011 Financial Results on March 7
    2. Stemline Therapeutics, Inc. Names Eric K. Rowinsky, M.D. Chief Medical Officer and Head of Research and Development
    3. Cell Therapeutics, Inc. Announces Institutional Investors Purchase $20 Million of Preferred Stock and Warrants
    4. Cell Therapeutics, Inc. (CTI) to Present at 10th Annual BIO Investor Forum
    5. Womens Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets
    6. Reed V. Tuckson, M.D., Executive Vice President and Chief of Medical Affairs at UnitedHealth Group, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
    7. Intrinsic Therapeutics, Inc. Names Cary P. Hagan as President & CEO
    8. Rare Disease Therapeutics, Inc. Selects Accredo Health Group to Distribute Anascorp® for the Treatment of Centruroides Scorpion Sting Envenomation
    9. Prefilled Syringes: Devices, Therapeutics, Players, Markets and Prospects
    10. Dry Powder Inhalation: Devices, Drugs, Therapeutics, Markets and Forecasts
    11. Cell Therapeutics, Inc. (CTI) Reports Reduction in Operating Expenses and Net Losses for Second Quarter and First Half 2011 Compared to 2010, and Advances In Bringing Pixantrone to Market
    Post Your Comments:
    (Date:10/8/2015)... and PITTSBURGH , Oct. 8, 2015 ... global pharmaceutical company, will host a conference call and ... pm ET to review the value to be created ... ; TASE) through Mylan,s offer to acquire the company. ... which outlines the compelling proposition for Perrigo shareholders. Mylan,s ...
    (Date:10/8/2015)... -- Following months of investigation, Ross Feller Casey , LLP ... the anticoagulant Xarelto,s recommended dosage doesn,t work for as long ... on behalf of a Florida ... didn,t work as the manufacturer suggested. Ross Feller Casey ... behalf of clients from across the country with similar claims. ...
    (Date:10/8/2015)... CHARLOTTE, N.C. , Oct. 8, 2015  Clariant, a ... Healthcare Packaging manufacturing facility in Belen, New ... manufactured for healthcare applications, including desiccant canisters and packets ... Belen plant is the second Clariant site ... – to meet the ISO 15378:2011 standards, following only ...
    Breaking Medicine Technology:
    ... 2012 announces that a new market ... Vaccines - Top 10 Global ... This market research report package offers an in-depth ... future outlook for vaccines in top 10 global ...
    ... HAIKOU, China, March 15, 2012 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, ... the "Company"), a fully-integrated specialty pharmaceuticals company in China, today ... Full Year Highlights , ... from $74.4 million in fiscal year 2010. , Income ...
    Cached Medicine Technology:
    (Date:10/10/2015)... ... ... have to walk with crutches for the rest of my life," said an inventor from ... that would give me more independence and freedom would be amazing. This inspired me to ... developed the STRAP IN to enable an individual to walk with crutches without having to ...
    (Date:10/10/2015)... ... , ... Isabel Healthcare will participate in the Cerner Health Conference October 11-14, ... the Institute of Medicine’s latest report “Improving Diagnosis in Healthcare”, Isabel Healthcare will be ... providers and consumers to potentially reduce the chance of error. The report suggests that ...
    (Date:10/9/2015)... , ... October 09, 2015 , ... ... highly sought after internships at the pre-eminent organization in global health: the World ... eliminating social and health disparities. These internships are a mechanism for WHO to ...
    (Date:10/9/2015)... LINCOLN, R.I. (PRWEB) , ... October 09, 2015 , ... ... (NFPA), working smoke alarms can cut the risk of dying in reported home fires ... safety tips to make sure smoke alarms are property installed and maintained. , Half ...
    (Date:10/9/2015)... ... 09, 2015 , ... On Saturday, September 26, 2015, 48-year-old MS survivor and ... Spain. Representing both the USA and Sweden in the Speed and Power events, which ... Crosses, she was awarded 1 Silver and 4 Gold Medals. , “I remember looking ...
    Breaking Medicine News(10 mins):
    ... Kensey Nash Corporation (Nasdaq: KNSY ) ... New York Emerging Growth Institutional Investor Forum at The ... 24, 2009.Joseph W. Kaufmann, Kensey Nash,s CEO, will deliver ... The presentation materials will be available on the ...
    ... PT. RICHMOND, Calif., March 13 Transcept Pharmaceuticals, Inc. ... focused on the development and commercialization of proprietary products ... neuroscience, today announced it will report results for its ... market close. A conference call to review the results ...
    ... The American Parkinson Disease Association (APDA) and the National ... of Young Onset Parkinson Conferences; First to be held ... 13 The American Parkinson Disease Association,s ... Foundation,s (NPF) Young Onset Parkinson Network announced their first ...
    ... Finding suggests children with language disorders may benefit from ... Musical training enhances the ability to recognize emotion in ... musical training might benefit people with language problems and ... emotion in sound is a skill that translates across ...
    ... smartest decision, report says , , FRIDAY, March 13 (HealthDay ... drug plans available through Medicare don,t select the plan ... The report found that the more than 50 standalone ... the best value for their individual medical and financial ...
    ... Street has earned the number one spot in the ... of Outsourcing Customer Satisfaction Survey, 2008.Andrew DeVoe, CEO and ... recognition from the Health Insurance Industry and all our ... to excellence.""The fact that we have been ranked in ...
    Cached Medicine News:
    Symbia T6, a True Point SPECT·CT system, combines a dual-detector variable angle gamma camera with a six slice CT scanner for advanced oncology, neurology, and cardiology applications....
    ... ACOM.PC turns every standard PC into ... internists, and cardiologists can use their ... access to image data thanks to ... 3 format and the compatible storage ...
    ... Soarian Cardiovascular Enterprise is a comprehensive ... care continuum from admission to follow-up. ... image acquisition, and diagnostic tools from ... provide a single, longitudinal clinical repository ...
    ... accurate lesion assessment plays a ... the appropriate stent size and ... (IC3D), a highly precise three-dimensional ... now able to quickly quantify ...
    Medicine Products: